Validate VS Verify


To identify biomarkers as surrogate – primary or secondary- endpoints in clinical trials, the relevance and validity of biomarkers need to be determined. Relevance means that a biomarker will actually provide clinically relevant information. Validity refers to the need to characterize a biomarker’s effectiveness or utility as a surrogate endpoint.

Different purposes for the use of the data require different approaches: validate vs. verify.

Verification and validation procedures go hand-in-hand to prove that a laboratory biomarker assay meets its requirements, specifications and that it fulfills its intended purpose. These procedures are critical components of the quality management system used at Eurofins Central Laboratory.

Scroll Back to Top